This approach, designed to bind to the cell surface of the HER2 antigen, has demonstrated some biological activity in conjunction with HER2 treatments towards inhibiting the tumor growth of HER2–enriched cells [178,179]. This evidence concerns the gene ERBB2 and neoplasm.